Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation and Depletion: 2019-2024

Historic Depreciation and Depletion for Allogene Therapeutics (ALLO) over the last 5 years, with Mar 2024 value amounting to $3.6 million.

  • Allogene Therapeutics' Depreciation and Depletion rose 1.37% to $3.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $14.2 million, marking a year-over-year increase of 0.97%. This contributed to the annual value of $14.2 million for FY2023, which is 0.67% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Depreciation and Depletion of $3.6 million as of Q1 2024, which was up 2.24% from $3.5 million recorded in Q4 2023.
  • Allogene Therapeutics' 5-year Depreciation and Depletion high stood at $4.2 million for Q4 2021, and its period low was $1.8 million during Q3 2020.
  • Moreover, its 3-year median value for Depreciation and Depletion was $3.6 million (2023), whereas its average is $3.6 million.
  • In the last 5 years, Allogene Therapeutics' Depreciation and Depletion soared by 247.98% in 2020 and then declined by 27.68% in 2022.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Depreciation and Depletion stood at $1.8 million in 2020, then spiked by 130.04% to $4.2 million in 2021, then fell by 27.68% to $3.1 million in 2022, then increased by 13.33% to $3.5 million in 2023, then rose by 1.37% to $3.6 million in 2024.
  • Its Depreciation and Depletion stands at $3.6 million for Q1 2024, versus $3.5 million for Q4 2023 and $3.6 million for Q3 2023.